<DOC>
	<DOCNO>NCT01921855</DOCNO>
	<brief_summary>This first human study BAY86-6150 ( B0189 ) non-bleeding subject moderate severe congenital hemophilia A B without inhibitor . This randomized , double-blind , placebo-controlled , single-dose , dose escalation study . It design investigate safety , tolerability , potential immunogenicity , pharmacokinetic pharmacodynamic profile BAY86-6150 ( B0189 ) determine dose range dos examine subsequent study .</brief_summary>
	<brief_title>Study FVIIa Variant BAY86-6150 ( B0189 ) Subjects With Moderate Severe Hemophilia Types A B With Without Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>History moderate severe congenital hemophilia A B without inhibitor Factor VIII ( FVIII ) Factor IX ( FIX ) Male subject 1865 year age inclusive Able dismiss factor replacement therapy course study unless require treatment acute bleed episode Written inform consent Willing able comply requirement protocol Have adequate venous access Willing use effective method contraception Day 30 study participation Received factor replacement therapy treatment procoagulant therapeutic , antifibrinolytic agent , include blood product , anytime within 5 day prior administration investigational medicinal product ( IMP ) Planned administration factor replacement therapy treatment procoagulant therapeutic antifibrinolytic agent , include blood product , anytime study period Acute bleeding episode ongoing bleed episode time within 7 day prior administration IMP Clinically relevant coagulation disorder congenital hemophilia A B History angina receive treatment angina History coronary atherosclerotic disease , disseminate intravascular coagulopathy , stage 2 hypertension define systolic blood pressure ( SBP ) &gt; /= 160 mmHg diastolic blood pressure ( DBP ) &gt; /= 90 mmHg History transient ischemic attack , stroke , myocardial infarction , coronary artery disease , congestive heart failure , thromboembolic event Active infection day IMP administration septicemia time within 30 day prior administration IMP</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>